SkinBioTherapeutics (LON:SBTX) Issues Earnings Results

SkinBioTherapeutics (LON:SBTX) announced its quarterly earnings data on Wednesday. The company reported GBX (0.46) (($0.01)) earnings per share for the quarter, Digital Look Earnings reports. SkinBioTherapeutics had a negative return on equity of 115.86% and a negative net margin of 237.95%.

SkinBioTherapeutics Trading Down 0.4 %

Shares of SBTX traded down GBX 0.10 ($0.00) on Friday, reaching GBX 24 ($0.31). 575,179 shares of the company’s stock were exchanged, compared to its average volume of 817,032. The business has a 50 day moving average price of GBX 20.16 and a two-hundred day moving average price of GBX 16.70. SkinBioTherapeutics has a 12 month low of GBX 8.32 ($0.11) and a 12 month high of GBX 26.45 ($0.34). The stock has a market capitalization of £54.82 million, a P/E ratio of -14.76 and a beta of 2.01. The company has a current ratio of 0.93, a quick ratio of 10.01 and a debt-to-equity ratio of 27.57.

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.